CD27 and CD70 Pathway

Introduction to CD27 and CD70 Pathway

CD27, also known as TNFRSF7, is a member of the tumor necrosis factor receptor (TNFR) superfamily. It has been served as the promising co-stimulatory immune checkpoint molecule for anti-cancer drug discovery. CD27 is expressed on naïve and activated T cells, NK cells, and activated B cells.

CD70, also known as CD27L or TNFSF7, is a typical representative of the tumor necrosis factor (TNF) ligand superfamily (TNFSF). CD70 is expressed as a single spanning transmembrane protein with an extracellular domain. CD70 is expressed by T cells, B-cells, lymphomas, and a considerable fraction of solid tumors. CD70 strongly stimulates the expression of CD27 and also CD27-associated signaling pathways. As a ligand-receptor pair of the TNF ligand and receptor family, CD70 and CD27 play essential roles in T-cell costimulation.

Research and Drugs for CD27 and CD70 Pathway

The CD27 and CD70 pathway presents a series of functions to regulate the T cell response in different stages. The mechanisms of actions including:

• Promote survival of activated conventional CD4⁺ and CD8⁺ T cells via antiapoptotic and prometabolic effects.
• Promote effector differentiation of activated CD4⁺ T cells towards a Th1 phenotype.
• Inhibit the iTreg and Th17 differentiation.
• Promote effector and memory differentiation of activated CD8⁺ T cells.
• Promote survival of effector T cells in nonlymphoid tissue according to stimulation autocrine IL-2 production.
• Promote the formation of memory T cells.
• Promote Treg survival/expansion by IL-2.

As the promising target for cancer treatment, a series of drugs targeting the CD27 and CD70 pathway have been discovered.

Fig.1 Mechanisms of action of the CD27/CD70 co-stimulatory system in the regulation of the T-cell response. (Van, 2015)

Services at Creative Biolabs

Equipped with advanced platforms and extensive experience, Creative Biolabs is proud to help our clients with immune checkpoint drug discovery. Based on our extensive experience on CD27 and CD70 pathway, now we can provide a series of services, including but not limited to:

• Immune Checkpoint Antibody Development
• Immune Checkpoint Targeted Small Molecule Drug Development
• Immune Checkpoint Assays
• Custom Immune Checkpoint Protein Development
• Immune Checkpoint Targeted Peptide Development
• Preclinical Research for Immune Checkpoint Drugs

If you are interested in our services, please do not hesitate to contact us for more detailed information.

Reference

1. Van, D.V.K.; Borst, J. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy. 2015, 7(6): 655-667.

All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic, or any in vivo human use.